H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $80.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments